721 results on '"Moskowitz, Alison J."'
Search Results
2. Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)
3. Brentuximab vedotin and chemotherapy in relapsed/refractory Hodgkin lymphoma: a propensity score–matched analysis
4. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
5. Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
6. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
7. Retrospective characterization of nodal marginal zone lymphoma
8. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
9. EXABS-208-HL Sequencing Novel Agents in Frontline and Second-Line Treatment of Hodgkin Lymphoma
10. What is the best salvage therapy for Hodgkin lymphoma?
11. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
12. Other New Agents for Hodgkin Lymphoma
13. Current Treatment of Peripheral T-cell Lymphoma
14. A Novel JAK2 Fusion in T‐Cell Prolymphocytic Leukemia.
15. BEAM versus pharmacokinetics‐directed BuCyVP16 conditioning for patients with peripheral T‐cell lymphoma undergoing high‐dose therapy with autologous hematopoietic cell transplantation.
16. Angioimmunoblastic T-Cell Lymphoma
17. Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma
18. Hodgkin Lymphoma: Next Questions
19. Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma
20. Other New Agents for Hodgkin Lymphoma
21. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
22. The Role of PI3K Inhibition in Lymphoid Malignancies
23. Novel Immunotherapies for T Cell Lymphoma and Leukemia
24. Do all patients with primary refractory/first relapse of HL need autologous stem cell transplant?
25. TP53mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
26. Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
27. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
28. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
29. Accelerated Total Lymphoid Irradiation-containing Salvage Regimen for Patients With Refractory and Relapsed Hodgkin Lymphoma: 20 Years of Experience
30. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups
31. Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma
32. Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma.
33. Angioimmunoblastic T-Cell Lymphoma
34. Other New Agents for Hodgkin Lymphoma
35. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II–IV peripheral T‐cell lymphoma
36. Supplementary Figure Legends from The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
37. Supplementary Figure S1 from The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
38. Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting
39. Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma
40. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
41. Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma
42. Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma
43. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
44. Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma
45. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?
46. Emapalumab for Malignancy-Associated Hemophagocytic Lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center Experience
47. Outcomes for Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma in the 21st Century By Relapse Status, Salvage Therapy, and Receipt of Allogeneic Transplant
48. Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
49. Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
50. Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.